Inovio Pharmaceuticals Inc (NASDAQ:INO) reported a drop of 3.6% or 429,151 shares in its short interest. The short figure came in at 20.3% of the total floats. The average daily volume of 504,873 shares suggests that the days to cover 11,508,677 short positions, as on January 15,2015, will be 23. On December 31,2014, the short interest was 11,937,828 shares. Inovio Pharmaceuticals Inc (NASDAQ:INO) has lost 1.82% during the past week and dropped 8.01% in the past 4 weeks. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 3.38%. Inovio Pharmaceuticals Inc (NASDAQ:INO) has underperformed the index by 6.36% in the past 4 weeks. Investors should watch out for further signals and trade with caution.
Inovio Pharmaceuticals Inc (NASDAQ:INO) remained unchanged at close of the session. Even as the volume increased to 357,614 shares, the counter failed to make any impression and ended at $8.5. The trading session commenced at $8.49 and the stock hit a high of $8.55 and touched $8.32 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $15.8 and the 52-week low is $7.48. The company has a market cap of $515 million and has approximately 60,591,000 outstanding shares.
Inovio Pharmaceuticals, Inc. is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Companys SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Companys electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. The Companys clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines
Sentiment: Strong Buy
Dr. Gelder brings well over a decade of experience in the pharmaceutical industry. Prior to joining Inovio, Dr. Gelder was Chief Medical Officer at Heron Therapeutics, an oncology-focused biotechnology company. Dr. Gelder's previous experience includes leading therapeutic oncology programs at Pfizer, Wyeth and Bayer, where he was involved in the approval and launch of several cancer therapeutics. He has led international trials, developed global product launch plans, and directed the development and execution of phase I to phase IV studies.
Dr. Gelder received his M.D. from the University of Virginia School of Medicine and completed residency training in internal medicine and OB/GYN followed by a gynecologic oncology fellowship. He is a Fellow of the American College of Physicians and the American College of Obstetrics and Gynecology and has extensive clinical experience in both the academic and private practice settings. Prior to joining the industry, Dr. Gelder was an investigator in multiple clinical trials and has authored numerous scientific papers in the areas of women's health and oncology.
Dr. J. Joseph Kim, President and CEO, said, "We are extremely pleased to bring a gynecology- oncology expert like Mark Gelder to lead our HPV immuno-oncology programs. Mark's extensive global experience in oncology and his standing as a respected OB/GYN opinion leader will strongly support Inovio as we bring the first DNA-based immunotherapies for HPV-associated diseases into medical practice."
In 2014, Inovio reported top-line data from a large, controlled phase II study showing that VGX-3100 was able to eliminate HPV infection and cause complete regression of high grade cervical dysplasia (CIN 2/3). Inovio is taking the steps to publish a paper with the full data set in a peer-reviewed medical journal this year. Based on the results of the phase II, Inovio plans to initiate a phase III study in early 2016.
Inovio has also expanded clinical development of its DNA-based immune therapy products to treat different HPV types and the many diseases they cause by conducting clinical trials for HPV-associated cervical cancer, aero-digestive cancers and head and neck cancer, the fastest growing cancer in men. Interim safety and immunogenicity data from these studies are expected in 2015.
clinical development of Cervical Dysplasia and cancer program...He must have liked what he saw prior to joining the team. Common sense, but wont be understood by all here that post..
Sentiment: Strong Buy
Something seems to be cooking...too big a move with out some strength..someware in the background..
Sentiment: Strong Buy
Very nice find..thanks..
Inovio Pharmaceuticals Inc (NASDAQ:INO): 5 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $22.2 in Inovio Pharmaceuticals Inc (NASDAQ:INO). However, the stock price could fluctuate by $ 4.32 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $29 price target with the lower price estimate is calculated at $19
Many Analysts from different Brokerage Firms have commented on the company rating and price targets.Inovio Pharmaceuticals Inc (NASDAQ:INO) has lost 7.59% during the past week and dropped 7.49% in the past 4 weeks. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 6.43%. Inovio Pharmaceuticals Inc (NASDAQ:INO) has underperformed the index by 5.14% in the past 4 weeks. Investors should watch out for further signals and trade with caution.
research ..next 12 mo. will be interesting seems all is on target..I didn't hear any downside but did hear a lot of potential break throughsSomething has got to stick so....It's but and hold
The number has doubled since the R/S but at the expense of the share holders ..you state you cant see how it couldn't have gone lower..didn't we go into the 8 dollar range again at the shareholders expense again? If the r/s was done with some substance behind it ,it would have worked for ALL concerned. Not just giving the funds a buying opp.
D..You said it all....The Science REMAINS compelling as do the Results..and if it works as indicated this could be the home run of home runs..It's not the science I'm pizzed at, its the way the management handles the over all picture of it.To spite them ,I'm still in but venting..(as you) they never miss an opportunity to shoot themselves in the foot!
Lets talk about the forbidden subject...R/S.At one point prior,we could have only gone down 2.57 or so then. Now we have 9.49 to achieve the same goal..So now ..What did the R/S do for us with out solid support to bolster the price forward.what we got was smoke and mirrors all with good intentions, but nothing to sink our teeth into..I'm still in,for some reason I'm hoping they are much better scientists then they are business men.I'll say it again,it was a fools move and now were paying for it. Down to the wire and nothing ...30 days to put up or shut up!! I don't know how you feel but I think dr. kims gun has no bullets.Id like nothing better than to be proven wrong. NO dwarfing...no low hanging fruit and not a sound.Its your money,be blind if you like..
Not to say your not a breath of fresh air yourself my friend..you understand me better than my psychologist ..I try not to have to much trouble with my ophthalmologist, if anyone understands what I'm saying...its you..